Abstract:Epilepsy refers to a disabling neurological disorder featured by the long-term and unpredictable occurrence of seizures owing to abnormal excessive neuronal electrical activity and is closely linked to unresolved inflammation, oxidative stress, and hypoxia. The difficulty of accurate localization and targeted drug delivery to the lesion hinders the effective treatment of this disease. The locally activated inflammatory cells in the epileptogenic region offer a new opportunity for drug delivery to the lesion. In this work, CD163-positive macrophages in the epileptogenic region were first harnessed as Trojan horses after being hijacked by targeted albumin manganese dioxide nanoparticles, which effectively penetrated the brain endothelial barrier and delivered multifunctional nanomedicines to the epileptic foci. Hence, accumulative nanoparticles empowered the visualization of the epileptogenic lesion through microenvironment-responsive MR T1-weight imaging of manganese dioxide. Besides, these manganese-based nanomaterials played a pivotal role in shielding neurons from cell apoptosis mediated by oxidative stress and hypoxia. Taken together, the present study provides an up-to-date approach for integrated diagnosis and treatment of epilepsy and other hypoxia-associated inflammatory diseases. Statement of significance The therapeutic effects of antiepileptic drugs (AEDs) are hindered by insufficient drug accumulation in the epileptic site. Herein, we report an efficient strategy to use locally activated macrophages as carriers to deliver multifunctional nanoparticles to the brain lesion. As MR-responsive T1 contrast agents, multifunctional BMC nanoparticles can be harnessed to accurately localize the epileptogenic region with high sensitivity and specificity. Meanwhile, catalytic nanoparticles BMC can synergistically scavenge ROS, generate O 2 and regulate neuroinflammation for the protection of neurons in the brain.

Nanocarriers in the treatment of epilepsy: Challenges and opportunities

Nanotechnological Advances in the Treatment of Epilepsy: A Comprehensive Review

A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications.

Fighting Epilepsy with Nanomedicines—Is This the Right Weapon?

Lamotrigine Lipid Nanoparticles for Effective Treatment of Epilepsy: a Focus on Brain Targeting via Nasal Route

Nanoparticles As a Carrier System for Drug Delivery Across Blood Brain Barrier

Nanoengineered on-demand drug delivery system improves efficacy of pharmacotherapy for epilepsy

Unveiling the effects of nanoparticles-based antiepileptic drugs: Systematic review of in vivo studies

Targeted nanotheranostics for the treatment of epilepsy through in vivo hijacking of locally activated macrophages

Nanomedicine revolutionizes epilepsy treatment: overcoming therapeutic hurdles with nanoscale solutions

A review of chitosan-based nanocarriers as drug delivery systems for brain diseases: Critical challenges, outlooks and promises

The electro-responsive nanoliposome as an on-demand drug delivery platform for epilepsy treatment

Recent Advances on Drug Delivery Nanocarriers for Cerebral Disorders.

Dual Targeting Nanoparticles for Epilepsy Therapy.

Recent progress in nanoparticulate-based intranasal delivery for treating of different central nervous system diseases

Nanotechnology-based Nose-to-brain Delivery in Epilepsy: A Novel Approach to Diagnosis and Treatment.

Recent Progress of Drug Nanoformulations Targeting to Brain

Strategic nanocarriers to control neurodegenerative disorders: Concept, challenges, and future perspective

Challenges and prospects in geriatric epilepsy treatment: the role of the blood–brain barrier in pharmacotherapy and drug delivery

ROS-removing Nano-Medicine for Navigating Inflammatory Microenvironment to Enhance Anti-Epileptic Therapy

Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.